- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07450547
Fas 2-studie för att utvärdera säkerheten och effektiviteten av ANG003
En fas 2, multicentrisk, randomiserad, aktivt kontrollerad studie för att bedöma säkerheten och effekten av ANG003 vid två olika dosnivåer hos patienter med exokrin pankreasinsufficiens på grund av cystisk fibros
In this study, ANG003, a pancreatic enzyme replacement therapy (PERT; commonly called "enzymes"), is being investigated as a potential treatment for exocrine pancreatic insufficiency (EPI). People with EPI due to Cystic Fibrosis (CF) may be eligible to participate in this study. The primary objective of this study is to evaluate the safety of ANG003 and see if it works as well compared to Creon, an approved PERT.
Studieöversikt
Status
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Evan Bailey, MD
- Telefonnummer: 617-466-3111
- E-post: medical@anagramtx.com
Studieorter
-
-
California
-
Long Beach, California, Förenta staterna, 90806
- Rekrytering
- Long Beach Memorial Medical Center
-
Kontakt:
- Angelica Rodriguez
- Telefonnummer: 562-706-1245
- E-post: ARodriguez9@memorialcare.org
-
Los Angeles, California, Förenta staterna, 90033
- Rekrytering
- Center for Cystic Fibrosis at Keck Medical Center of USC
-
Kontakt:
- Lynn Fukushima
- Telefonnummer: 323-442-8522
- E-post: lynn.fukushima@med.usc.edu
-
-
Colorado
-
Denver, Colorado, Förenta staterna, 80206
- Rekrytering
- National Jewish Health
-
Kontakt:
- Alix Wilson
- Telefonnummer: 303-270-2517
- E-post: wilsona@njhealth.org
-
-
Florida
-
Gainesville, Florida, Förenta staterna, 32610
- Har inte rekryterat ännu
- University of Florida
-
Kontakt:
- Alexa Smith
- Telefonnummer: 352-273-8380
- E-post: alexa.howell@ufl.edu
-
Orlando, Florida, Förenta staterna, 32803
- Har inte rekryterat ännu
- Central Florida Pulmonary Group
-
Kontakt:
- Desiree Serr
- Telefonnummer: 407-303-7192
- E-post: desiree.serr1@adventhealth.com
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30324
- Rekrytering
- Emory-Children's Healthcare of Atlanta Cystic Fibrosis Center
-
Kontakt:
- Eric Hunter
- Telefonnummer: 678-977-5212
- E-post: eahunte@emory.edu
-
-
Illinois
-
Glenview, Illinois, Förenta staterna, 60025
- Rekrytering
- The Cystic Fibrosis Institute
-
Kontakt:
- Steven R Boas, MD
- Telefonnummer: 847-998-3434
- E-post: sboas@wecare4lungs.com
-
-
Iowa
-
Iowa City, Iowa, Förenta staterna, 52242
- Har inte rekryterat ännu
- University of Iowa
-
Kontakt:
- Mary Teresi
- Telefonnummer: 319-384-7546
- E-post: mary-teresi@uiowa.edu
-
-
Kansas
-
Kansas City, Kansas, Förenta staterna, 66160
- Rekrytering
- University of Kansas Medical Center
-
Kontakt:
- Lawrence Scott
- Telefonnummer: 913-588-4020
- E-post: lscott2@kumc.edu
-
-
Kentucky
-
Lexington, Kentucky, Förenta staterna, 40506
- Rekrytering
- University of Kentucky
-
Kontakt:
- Chase Whitaker
- Telefonnummer: 859-218-4810
- E-post: chase.whitaker@uky.edu
-
-
Maine
-
Portland, Maine, Förenta staterna, 04102
- Har inte rekryterat ännu
- MaineHealth Pediatric Specialty Care
-
Kontakt:
- Rebecca Edwards
- Telefonnummer: 207-662-6712
- E-post: rebecca.edwards@mainehealth.org
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02114
- Rekrytering
- Massachusetts General Hospital
-
Kontakt:
- Margot Hardcastle
- Telefonnummer: 617-726-3719
- E-post: mhardcastle@mgh.harvard.edu
-
Boston, Massachusetts, Förenta staterna, 02115
- Rekrytering
- Boston Children's Hospita
-
Kontakt:
- Robert Fowler
- Telefonnummer: 617-355-1834
- E-post: Robert.fowler@childrens.harvard.edu
-
-
Michigan
-
Ann Arbor, Michigan, Förenta staterna, 48109
- Rekrytering
- University of Michigan, Michigan Medicine
-
Kontakt:
- Dawn Kruse
- Telefonnummer: 734-615-3266
- E-post: dmkruse@med.umich.edu
-
Detroit, Michigan, Förenta staterna, 48201
- Rekrytering
- Wayne State University Harper University Hospital
-
Kontakt:
- Debra Driscoll
- Telefonnummer: 313-745-2221
- E-post: ddriscol@med.wayne.edu
-
-
Minnesota
-
Minneapolis, Minnesota, Förenta staterna, 55455
- Rekrytering
- University of Minnesota
-
Kontakt:
- Brooke Noren, RN, BSN, CCRC
- Telefonnummer: 612-625-7995
- E-post: boer0039@umn.edu
-
-
New Jersey
-
New Brunswick, New Jersey, Förenta staterna, 08903
- Rekrytering
- Rutgers - Robert Wood Johnson Medical School
-
Kontakt:
- Sheila Redding
- Telefonnummer: 732-235-7840
- E-post: sr1238@rwjms.rutgers.edu
-
-
New York
-
Valhalla, New York, Förenta staterna, 10595
- Har inte rekryterat ännu
- New York Medical College at Westchester Medical Center
-
Kontakt:
- Zachary Messer
- Telefonnummer: 914-594-2352
- E-post: Zachary_Messer@nymc.edu
-
-
Ohio
-
Akron, Ohio, Förenta staterna, 44308
- Rekrytering
- Children's Hospital Medical Center of Akron
-
Kontakt:
- Michelle Parrish
- Telefonnummer: 330-543-3089
- E-post: MParrish@akronchildrens.org
-
Cleveland, Ohio, Förenta staterna, 44106
- Rekrytering
- Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center
-
Kontakt:
- Primary RC & Participant Contact General Contact
- Telefonnummer: 216-844-3911
- E-post: RainbowCFResearch@UHhospitals.org
-
Columbus, Ohio, Förenta staterna, 43205
- Rekrytering
- Nationwide Children's Hospital, Columbus
-
Kontakt:
- Diana Gilmore
- Telefonnummer: 614-722-4752
- E-post: diana.gilmore@nationwidechildrens.org
-
Toledo, Ohio, Förenta staterna, 43606
- Rekrytering
- Toledo Children's Hospital
-
Kontakt:
- Kelly Hoot
- Telefonnummer: 419-291-4630
- E-post: kelly.hoot@promedica.org
-
-
Pennsylvania
-
Hershey, Pennsylvania, Förenta staterna, 17033
- Rekrytering
- Hershey Medical Center Pennsylvania State University
-
Kontakt:
- Diane Kitch
- Telefonnummer: 717-531-5646
- E-post: dkitch@pennstatehealth.psu.edu
-
Pittsburgh, Pennsylvania, Förenta staterna, 15224
- Har inte rekryterat ännu
- University of Pittsburgh Medical Center
-
Kontakt:
- Adrienne DeRicco
- Telefonnummer: 412-692-8069
- E-post: adrienne.dericco2@upmc.edu
-
-
Texas
-
Dallas, Texas, Förenta staterna, 75207
- Rekrytering
- University of Texas Southwestern / Children's Health
-
Kontakt:
- Keianna Brown
- Telefonnummer: 214-456-5489
- E-post: Keianna.brown@utsouthwestern.edu
-
-
Utah
-
Salt Lake City, Utah, Förenta staterna, 84112
- Rekrytering
- Adult Cystic Fibrosis Center at the University of Utah
-
Kontakt:
- Kristyn Packer
- Telefonnummer: 801-520-5106
- E-post: kristyn.packer@hsc.utah.edu
-
-
Wisconsin
-
Madison, Wisconsin, Förenta staterna, 53792
- Rekrytering
- University of Wisconsin
-
Kontakt:
- Melanie Nelson
- Telefonnummer: 608-265-4617
- E-post: mnelson@pediatrics.wisc.edu
-
Milwaukee, Wisconsin, Förenta staterna, 53226
- Har inte rekryterat ännu
- Froedtert & Medical College of Wisconsin
-
Kontakt:
- Erin Hubertz
- Telefonnummer: 414-955-7019
- E-post: ehubertz@mcw.edu
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
Male and female subjects aged ≥12 years from the date of informed consent in the US and aged ≥18 years in the EU
-
Confirmed and documented diagnosis of CF
-
Diagnosed with severe EPI as defined by a fecal elastase ≤50 μg/g stool measured at Screening by a central laboratory.
-
Subject has controlled EPI and taking a stable dose of pancreatic enzyme replacement therapy (PERT) for 90 days prior to Screening.
-
Adequate nutritional status measured by body mass index (BMI) defined by:
- BMI ≥25th percentile for children aged 12-17 years
- BMI ≥18.5 kg/m2 for ≥18 years of age
Exclusion Criteria:
- History of fibrosing colonopathy or recurring distal intestinal obstructive syndrome within 6 months of Screening.
- History of lung or liver transplant, listing for organ transplant or significant bowel resection within the last 6 months. Subjects with a history of resection that does not result in short bowel syndrome are eligible.
- Known hypersensitivity or other severe reaction to any ingredient of the investigational product (IP), Creon, or the stool marker (FD&C Blue #2).
- Any chronic diarrheal illness unrelated to pancreatic insufficiency, actively being treated for small intestinal bacterial overgrowth, requiring use of naso-gastric, J-tube, G-tube, and/or enteral feeding for the study duration, Clostridioides difficile infection within 6 months prior to Screening, or severe constipation defined as <1 bowel movement/week.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: ANG003 Dose A
All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. If baseline CFA is >/= 80%, the subject may be randomized to ANG003 Dose A for a 21-day acclimation and subsequent CFA analysis. |
160,000 u* lipase, 105,000 u* protease, and 11,600 u* amylase per dose (*units are comparable to United States Pharmacopeiea [USP]) |
|
Experimentell: ANG003 Dose B
All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. If baseline CFA is >/= 80%, the subject may be randomized to ANG003 Dose B for a 21-day acclimation and subsequent CFA analysis. |
240,000 u* lipase, 105,000 u* protease, and 11,600 u* amylase per dose (*units are comparable to United States Pharmacopeiea [USP]) |
|
Aktiv komparator: Creon
All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. If baseline CFA is >/= 80%, the subject may be randomized to Creon for an additional 21-days and subsequent CFA analysis. |
The commercially available pPERT Creon will be the active comparator in the study. Subjects will be instructed to take Creon according to the package insert and PI direction. |
|
Inget ingripande: Off Enzyme
All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. If baseline CFA is >/= 80%, the subject may be randomized to the off enzyme arm. Subjects will receive Creon for an additional 21-day and the subsequent CFA analysis will be off enzyme. Total time off enzyme will be 4-7 days. |
|
|
Övrig: 60% to <80% CFA ANG003 Dose B
All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. Participants with a Period A CFA result of 60% to <80% will be assigned to ANG003 Dose B. |
240,000 u* lipase, 105,000 u* protease, and 11,600 u* amylase per dose (*units are comparable to United States Pharmacopeiea [USP]) |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Adverse events (AEs); Treatment-emergent AEs; Serious AEs; Discontinuation due to AEs; Clinical laboratory values
Tidsram: From Visit 1 to Visit 5, anticipated average 80 days
|
Adverse events (AEs); Treatment-emergent AEs; Serious AEs; Discontinuation due to AEs; Clinical laboratory values |
From Visit 1 to Visit 5, anticipated average 80 days
|
|
Coefficient of Fat Absorption (CFA)
Tidsram: Period A (baseline) and Period B 72 hour CFA collection
|
Mean change from baseline CFA (i.e., Period B CFA minus Period A CFA) assessed for ANG003 Dose A, ANG003 Dose B, and Creon amongst subjects with baseline CFA ≥80%. |
Period A (baseline) and Period B 72 hour CFA collection
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Plasma docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) (ug/mL)
Tidsram: Period A (baseline) and Period B time 0, 1, 2, 4, 6, 8, 10 and 24 hour collections
|
Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%. |
Period A (baseline) and Period B time 0, 1, 2, 4, 6, 8, 10 and 24 hour collections
|
|
Coefficient of Nitrogen Absorption (CNA)
Tidsram: Period A (baseline) and Period B 72 hour CNA collection
|
Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%. |
Period A (baseline) and Period B 72 hour CNA collection
|
|
% of subjects with GI symptoms
Tidsram: From Visit 2 to Visit 5, anticipated average 59 days
|
Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%. |
From Visit 2 to Visit 5, anticipated average 59 days
|
|
Cumulative stool weight
Tidsram: Period A (baseline) and Period B 72 hour collection
|
Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%. |
Period A (baseline) and Period B 72 hour collection
|
|
Number of Stools per Day
Tidsram: Period A (baseline) and Period B 72 hour collection
|
Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%. |
Period A (baseline) and Period B 72 hour collection
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Correlation between DHA/EPA and CFA
Tidsram: Period A (baseline) Period B 72 hour CFA and 24 hour DHA/EPA collection
|
Mean change from baseline for each treatment group with a baseline CFA ≥80% |
Period A (baseline) Period B 72 hour CFA and 24 hour DHA/EPA collection
|
|
Coefficient of Fat Absorption (CFA) for subjects with a baseline CFA of 60% to <80% (analyzed separately)
Tidsram: Period A (baseline) and Period B 72 hour CFA collection
|
Mean change from baseline for each treatment group with a baseline CFA 60% to <80% |
Period A (baseline) and Period B 72 hour CFA collection
|
|
Mean Period B CFA for all subjects randomized to the Off Enzyme arm with a baseline CFA ≥80%
Tidsram: Period B 72 hour CFA collection
|
Period B CFA Off Enzyme in subjects with a baseline CFA ≥80% |
Period B 72 hour CFA collection
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Genetiska sjukdomar, medfödda
- Luftvägssjukdomar
- Matsmältningssystemets sjukdomar
- Lungsjukdomar
- Spädbarn, nyfödda, sjukdomar
- Bukspottkörtelsjukdomar
- Medfödda, ärftliga och neonatala sjukdomar och abnormiteter
- Cystisk fibros
- Exokrin pankreasinsufficiens
- Hydrolaser
- Enzymer
- Enzymer och koenzymer
- Komplexa blandningar
- Lipas
- Karboxylesterhydrolaser
- Esteraser
- Bukspottkörtelextrakt
- Vävnadsextrakt
- Pankrelipas
Andra studie-ID-nummer
- ANG003-25-201
- 2025-524569-25-00 (Ctis)
- 2025 (U.S.S. NIH-anslag/kontrakt)
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .